<bill session="106" type="h" number="3665" updated="2013-07-14T18:54:34-04:00">
  <state datetime="2000-02-15">REFERRED</state>
  <status>
    <introduced datetime="2000-02-15"/>
  </status>
  <introduced datetime="2000-02-15"/>
  <titles>
    <title as="introduced" type="short">Prescription Price Equity Act of 2000</title>
    <title as="introduced" type="official">To amend the Internal Revenue Code of 1986 to deny tax benefits for research conducted by pharmaceutical companies where United States consumers pay higher prices for the products of that research than consumers in certain other countries.</title>
  </titles>
  <sponsor id="400387"/>
  <cosponsors>
    <cosponsor id="400525" joined="2000-04-13"/>
    <cosponsor id="400548" joined="2000-05-25"/>
    <cosponsor id="400087" joined="2000-06-08"/>
    <cosponsor id="400301" joined="2000-02-29"/>
  </cosponsors>
  <actions>
    <action datetime="2000-02-15">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E148"/>
    </action>
    <action state="REFERRED" datetime="2000-02-15">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="106" type="s" number="2465"/>
  </relatedbills>
  <subjects>
    <term name="Taxation"/>
    <term name="Business income tax"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Consumer protection"/>
    <term name="Costs"/>
    <term name="Depreciation and amortization"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Exports"/>
    <term name="Foreign trade and international finance"/>
    <term name="Health"/>
    <term name="OECD countries"/>
    <term name="Orphan drugs"/>
    <term name="Pharmaceutical research"/>
    <term name="Prescription pricing"/>
    <term name="Price discrimination"/>
    <term name="Research and development tax credit"/>
    <term name="Science, technology, communications"/>
    <term name="Tax deductions"/>
  </subjects>
  <amendments/>
  <summary>2/15/2000--Introduced.
Prescription Price Equity Act of 2000 - Amends the Internal Revenue Code to deny, to any taxpayer who is a member of a worldwide affiliated group with any disqualified gross receipts from any developed foreign country, the applicable percentage of the research-related tax benefits.Defines the term "disqualified gross receipts" to mean, with respect to any developed foreign country, gross receipts of the worldwide affiliated group from prescription drugs manufactured or produced by any member of such group and sold for use or consumption in such country if such gross receipts are at least five percent less than the amount which would be such gross receipts were such drugs sold at their respective average manufacturing prices charged by members of such group in the United States. Defines, in addition, the terms "developed foreign country," "applicable percentage," and "research-related tax benefits."</summary>
</bill>
